Search PubMed⌕ Search

Biomedical subjects

Muthana S Al-Ghazi

Publications and source records attributed to Muthana S Al-Ghazi.

4 recordsLinked to original sources

Real-time tumor tracking using implanted positron emission markers: concept and simulation study.

The delivery accuracy of radiation therapy for pulmonary and abdominal tumors suffers from tumor motion due to respiration. Respiratory gating should be applied to avoid the use of a large target volume margin that results in a substantial dose to the surrounding normal tissue. Precise respiratory gating requires the exact spatial position of the tumor to be determined in real time during treatment. Usually, fiducial markers are implanted inside or next to the tumor to provide both accurate patient setup and real-time tumor tracking. However, current tumor tracking systems require either substantial x-ray exposure to the patient or large fiducial markers that limit the value of their application for pulmonary tumors. We propose a real-time tumor tracking system using implanted positron emission markers (PeTrack). Each marker will be labeled with low activity positron emitting isotopes, such as 124I, 74As, or 84Rb. These isotopes have half-lives comparable to the duration of radiation therapy (from a few days to a few weeks). The size of the proposed PeTrack marker will be 0.5-0.8 mm, which is approximately one-half the size of markers currently employed in other techniques. By detecting annihilation gammas using position-sensitive detectors, multiple positron emission markers can be tracked in real time. A multimarker localization algorithm was developed using an Expectation-Maximization clustering technique. A Monte Carlo simulation model was developed for the PeTrack system. Patient dose, detector sensitivity, and scatter fraction were evaluated. Depending on the isotope, the lifetime dose from a 3.7 MBq PeTrack marker was determined to be 0.7-5.0 Gy at 10 mm from the marker. At the center of the field of view (FOV), the sensitivity of the PeTrack system was 240-320 counts/s per 1 MBq marker activity within a 30 cm thick patient. The sensitivity was reduced by 45% when the marker was near the edge of the FOV. The scatter fraction ranged from 12% (124I, 74As) to 16% (84Rb). In addition, four markers (labeled with 124I) inside a 30 cm diameter water phantom were simulated to evaluate the feasibility of the multimarker localization algorithm. Localization was considered successful if a marker was localized to within 2 mm from its true location. The success rate of marker localization was found to depend on the number of annihilation events used and the error in the initial estimate of the marker position. By detecting 250 positron annihilation events from 4 markers (average of 62 events per marker), the marker success rates for initial errors of +/-5, +/-10, and +/-15 mm were 99.9%, 99.6%, and 92.4%, respectively. Moreover, the average localization error was 0.55 (+/-0.27) mm, which was independent of initial error. The computing time for localizing four markers was less than 20 ms (Pentium 4, 2.8 GHz processor, 512 MB memory). In conclusion, preliminary results demonstrate that the PeTrack technique can potentially provide real-time tumor tracking with low doses associated with the marker's activity. Furthermore, the small size of PeTrack markers is expected to facilitate implantation and reduce patient risk.

Algorithms↗

Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.

OBJECTIVE(S): To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer. METHODS: Viable primary untreated cervical cancer specimens were obtained and exposed to gamma irradiation at a dose of 3 Gy in the IVRRA to determine in vitro radiation sensitivity. RNA was purified for microarray analysis with the Affymetrix Human Genome U95A Array carrying more than 12,000 gene probes. Gene expression analysis was performed, and specimen transcript patterns were correlated with radiation response using an iteration analysis model and Pearson's correlation coefficient. RESULTS: A feasibility set of eight tumor specimens was studied. Tumors were classified into 4 extreme (ERR), 2 intermediate (IRR) and 2 low radiation resistance (LRR) categories. An intrinsic radiation response gene set of 54 genes transcripts with 100% accuracy for the classification of each tumor's radiation response category was identified. CONCLUSION(S): Gene sets associated with in vitro radiation response profiles in cervical cancer can be generated using the IVRRA and microarray technology. This has direct applications to the study of the biological pathways contributing to radiation resistance and may lead to the development of alternative treatment modalities. The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation.

Feasibility Studies↗

Treatment planning considerations of reshapeable automatic intensity modulator for intensity modulated radiation therapy.

As compared with multi-leaf collimator based intensity modulated radiation therapy (IMRT) techniques, physical modulators have the major advantage of temporally invariant intensity map delivery which makes it more flexible with monitor unit rate, simpler resolution of interrupted treatment and easier implementation and use with respiratory gating. However, traditional physical modulator techniques require long fabrication time and operator intervention during treatments. It has been previously proposed [Xu et al., Med. Phys. 29, 2222-2229 (2002)] that a reshapeable automatic intensity modulator (RAIM) can automatically produce physical modulators by molding a deformable high x-ray attenuation material using a matrix of computer-controlled pistons. RAIM can potentially eliminate the limitations of traditional physical modulators. The present study addresses the treatment planning considerations of RAIM for IMRT. In this study, a 3D treatment-planning system (PLUNC) was modified to include the capability of providing treatment planning using RAIM. Two clinically representative cases were studied: nasopharyngeal and prostate tumors. First, the RAIM system with two different spatial resolutions at isocenter, 1 x 1 cm2 and 0.5 x 0.5 cm2, were evaluated. The treatment planning results of RAIM were then compared with other IMRT techniques such as smooth modulator with ideal (100%-2%) and limited (100%-13%) intensity modulation ranges, segmental multi-leaf collimator (SMLC) with ten intensity levels, 1 cm leaf width and 0.5 cm step size and serial tomotherapy using the Peacock system. Bringing the spatial resolution of RAIM down to 0.5 x 0.5 cm2 did not show improvement due to the effect of penumbra. The RAIM system with 1 x 1 cm2 proved slightly inferior as compared to the ideal smooth physical modulator but better than the SMLC technique and the smooth modulator with limited modulation range. When compared to serial tomotherapy, RAIM is only inferior in brain stem sparing for the nasopharynx case. Furthermore, the RAIM system with 1 x 1 cm2 resolution required significantly lower monitor units as compared to the other IMRT techniques for the two cases studied.

Algorithms↗

Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma.

This is a retrospective analysis of a new treatment modality, intra-arterial administration of Yttrium-90 TheraSphere, for unresectable hepatocellular carcinoma (HCC). Patients with HCC not amenable to surgical treatment who had satisfactory physiological function without comorbid disease or significant pulmonary shunting were eligible for treatment. Patients were categorized into complete, partial, or no response based on serum alpha-fetoprotein (AFP) levels and CT or MRI imaging. Fourteen patients were considered candidates for treatment. Three patients were excluded due to significant hepatopulmonary shunting. Eleven patients were treated with TheraSphere. One patient (9%) had a complete response, eight patients (78%) had a partial response, and two patients (18%) showed no response. Partial and complete responders with AFP-associated HCC demonstrated a median decrease in AFP levels of 79 per cent at 73 days. No patients developed liver toxicity nor died due to treatment. Five patients (45%) died of progressive disease at a median of 7 months post-treatment. Six patients (54%) were alive at a median of 11 months (range, 9 to 20 months). Okuda stage 2 and 3 patients showed a median survival of 11 months and 7 months, respectively. Yttrium-90 TheraSphere treatment for unresectable hepatocellular carcinoma is well tolerated and appears to extend survival.

Aged↗